Claim Missing Document
Check
Articles

Found 31 Documents
Search

ANALISIS TES IMUNOKROMATOGRAFI DAN ENZYME-LINKED IMMUNOSORBENT ASSAY UNTUK MENDETEKSI Helicobacter pylori DI PASIEN DISPEPSIA I Hutagalung; Uleng Bahrun; Mansyur Arif; Rifai Amirudin; HAM Akil
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 15, No 3 (2009)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v15i3.959

Abstract

Many methods are available to diagnose Helicobacter pylori in patients with dyspepsia, including Enzyme-Linked ImmunosorbantAssay (ELISA) and recently used is immnochromatography test. Both of the test are non invasive method, but immunochromatographytest can be used in laboratory without semi automatic analyzer. The aim of this study was to compare the immunochromatographyand ELISA tests in detecting the possibility of Helicobacter pylori infection. A cross sectional study was done among 49 sampleswith dyspepsia at Wahidin Sudirohusodo Hospital of Makassar and Prodia Laboratory from March to August 2008. Samples wereanalyzed with SPSS 14 for Windows Program using Chi Square and Spearman correlation tests. Among 49 samples we found ELISAand immunochromatography tests were positive in 5 samples, ELISA and immunochromatography tests were negative in 33 samples,ELISA tests were borderline and immunochromatography tests were positive in 5 samples, and ELISA tests were borderline andimmunochromatography tests were negative in 6 samples. There was a good correlation between ELISA and immunochromatographytest with R = 1.000 and p = 0.000. Both results of the immunochromatography and ELISA tests showed high conformity. Both methodcan be applied to diagnose Helicobacter pylori in patients with dyspepsia. Immunochromatography test can be an alternative methodin laboratories who do not apply semi automatic analyzer. The advantages of immunochromatography test can be used for diagnoseearly infection of Helicobacter pylori.
CORRELATION OF ANTINUCLEAR ANTIBODY PROFILE WITH HEMATOLOGIC AND RENAL DISORDERS IN SYSTEMIC LUPUS ERYTHEMATOSUS Chelvi Wijaya; Asvin Nurulita; Uleng Bahrun
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 23, No 2 (2017)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v23i2.1137

Abstract

Systemic Lupus Erythematosus (SLE) adalah penyakit autoimun dan bersifat multi organ. Kelainan hematologi sering ditemukandi penyakit ini, begitu juga dengan kelainan ginjal yang merupakan salah satu faktor yang sangat berpengaruh. Uji ANA profile dapatmengetahui subtipe antibodi antinuklear yang khas. Autoantibodi tersebut diduga berhubungan dengan manifestasi klinis. Penelitian inimerupakan penelitian analitik retrospektif di Laboratorium Patologi Klinik dan Instalasi Rekam Medik RSUP. Dr. Wahidin SudirohusodoMakassar dengan mengambil data hasil ANA profile, darah rutin dan urinalisis pasien terduga SLE masa waktu Januari 2014–Juli 2016.Data dikelompokkan menjadi SLE dan nonSLE. Analisis statitik dengan uji Chi Kuadrat dan Fisher. Dari 72 sampel, 39 dengan diagnosaakhir SLE. Terdapat hubungan bermakna antara anti RNP/Sm, Sm, SS-A, Ro-52, dsDNA, Nucleosome, Histone, Ribosomal P denganSLE (p<0,05). Terdapat hubungan bermakna antara anti dsDNA (p=0,029) dan anti nucleosome (p=0,037) dengan anemia serta antidsDNA (p=0,013) dan anti nucleosome (p=0,036) dengan gangguan ginjal. Tidak ditemukan hubungan bermakna antara autoantibodidalam penelitian ini dengan leukopenia, limfopenia dan trombositopenia. Anti RNP/Sm, Sm, SS-A, Ro-52, dsDNA, nucleosome, Histones,Ribosomal P berhubungan dengan SLE. Anti dsDNA dan anti nucleosome berhubungan dengan anemia dan gangguan ginjal padaSLE, sehingga mungkin dapat digunakan untuk meramalkan kejadian tersebut, walaupun dibutuhkan penelitian lanjutan untukmembuktikannya. Tidak ditemukan autoantibodi yang dapat dihubungkan dengan leukopenia, limfopenia dan trombositopenia.
PENILAIAN UJI TROPONIN I DENGAN POINT OF CARE TESTING Sheila Febriana; Asvin Nurulita; Uleng Bahrun
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 22, No 2 (2016)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v22i2.1112

Abstract

Troponin I is a cardiac biomarker recomended by The Third Global Myocardial Infarction Task Force World Health Organisation(WHO). Troponin plays a central role as a relevant biomarker that require reliable samples, methods, device and efficiency of time.Selecting the device, methods and sample used in the assay may affect the results and turn arround time. The aim of this study is toknow troponin I result using Point of care Testing device with a flourescence immunoassay methods using whole blood and laboratorybasedanalysis device with Enzyme-Linked Fluorescent Assay (ELFA) methods using serum by evaluation. Cross sectional study was heldon 50 subjects in Wahidin Sudirohusodo hospital during the period between July-August 2015, those who suspected suffering acutecoronary syndome (ACS) and underwent troponin I test ordered by the physician and also had whole blood sample. The subjects arearound 51.96±12.80 year old and most of them are men (62%). The mean consentration of troponin I with laboratoric-based analysis is0.50±1.69 μg/L and with POCT is 0.51±1.77. The Pearson correlation test shows the correlation (r) is 0.99 with the p value is <0.001.Bland and Altman methods show the mean difference between two assays is 0.014μg/L (95% confidence interval, -0.015; 0.043) withthe limit of agreement -0.19 to 0.22. Based on this study, it can be concluded that troponin I assay using POCT device can be used tosupport ACS diagnosis precisely and rapidly. It is suggested to perform futher study with concern on the patient’s clinical condition aswell as the diagnosis, so it can evaluate the device performance to measure troponin I levels consistently with the clinical condition.
ANALISIS ABSOLUTE NEUTROPHIL COUNT DI PASIEN KANKER PAYUDARA DENGAN KEMOTERAPI (Analysis of Absolute Neutrophil Count in Breast Cancer Patients with Chemotherapy) Arifa Moidady; Tenri Esa; Uleng Bahrun
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 21, No 3 (2015)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v21i3.1269

Abstract

The Absolute Neutrophil Count (ANC) is the absolute number of neutrophil derived from the multiplication of the relative number ofleukocytes to the total neutrophil count. Neutrophils can be disturbed due to myelosupressive effects of chemotherapy. Fever is a commonsymptom in neutropenia patients due to chemotherapy. This fever is an emergency requiring rapid handling of Oncology and needsadministration of appropriate antibiotics. Therefore, the data on the occurence of neutropenia and its related fever in patients whomaccept chemotherapy after breast cancer it is important to be noted. This study is carried on to know the Absolute Neutrophil Count(ANC) in breast cancer patients with chemotherapy by analyzing them. The study was performed retrospectively by taking medical recorddata from January up to December 2012 in Dr. Wahidin Sudirohusodo Hospital Makassar. The absolute Neutrophil Count pre and afterchemotherapy analysis was done to determine neutropenia, as well as the febrile neutropenia and the correlation between ANC withpatients age and stage of breast cancer. A total of 55 samples with the majority of patients (85.45%) were in the age group of 41–60years old. The ANC after chemotherapy occurred in 50 patients were decreased (90.91%). There are five (5) patients (9.09%) with feverand two (2) persons (patients) (3.63%) suffered febrile neutropenia. The correlation analysis between decreased ANC with patient ageand stage of breast cancer are p=0.054 and 0.070 respectively. Based on this study it can be concluded, that decreased ANC occurredin most patients after accepting chemotherapy but only few patients suffered febrile neutropenia. There was no significant correlationbetween the decreased ANC with patient age and stage of breast cancer.
IMUNOGLOBULIN A DI DEMAM BERDARAH DENGUE Iwan Joseph; Uleng Bahrun; Idham Jaya Ganda; Mansyur Arif
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 18, No 1 (2011)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v18i1.350

Abstract

Recently several serology tests have been used to detect IgM and IgG antidengue, and NS1 antigen. On the last study was launched a new diagnose test using immunochromatography method to detect the specific antidengue IgA antibody. The aim of this study was to evaluate the IgA antidengue performance using immunochromatography method in Dengue Hemorrhagic Fever patients. The study was carried out during March up to July 2010 by a cross sectional method. The samples taken were 1–14 year‘s old patients from the Infectious Tropical Sub Division of the Department of Paediatric, Dr. Wahidin Sudirohusodo Hospital, Makassar. The samples were diagnosed Dengue Hemorrhagic Fever based on the criteria of WHO 1997 and they also subjected to IgM and IgG serology tests as well. The test for IgA is using immunochromatography method. The data was analyzed by Spearman Correlation Test. From the total 40 samples, which consist of 16 (40%) male and 24 women (60%), generally were taken on the fourth day until the sixth day of onset. There were more IgA anti Dengue detected rather than IgM on the secondary infection. The researchers found moderate correlation among the IgA test with IgM (+), IgG (+), or both positive. Based on this study so far it can be concluded that the Dengue IgA test can be used to detect the primary or secondary Dengue virus infection.
CREATINE KINASE RELATED TO THE MORTALITY IN MYOCARDIAL INFARCTION (Creatine Kinase terhadap Angka Kematian di Infark Miokard) Liong Boy Kurniawan; Uleng Bahrun; Darmawaty Rauf; Mansyur Arif
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 23, No 1 (2016)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v23i1.1178

Abstract

Creatine Kinase (CK) merupakan salah satu uji yang sering diperiksakan untuk mendiagnosis infark miokard akut. Peningkatanenzim ini menunjukkan ada nekrosis sel otot meskipun tidak khas di otot jantung. Kenaikan tingkat CK di infark miokard akutmenggambarkan luas serta beratnya penyakit dan dihubungkan dengan peningkatan angka kematian pasien. Untuk mengetahui tingkatCK di pasien infark miokard akut saat masuk rumah sakit dan menilai pengaruhnya terhadap angka kematian pasien selama perawatandi rumah sakit. Penelitian ini merupakan kajian potong lintang dengan mengambil data sekunder dari rekam medik 62 pasien infarkmiokard akut yang dirawat di Unit Perawatan Jantung Intensif Rumah Sakit Dr. Wahidin Sudirohusodo Makassar masa waktu bulanJuli 2010 hingga Juni 2011. Kadar CK yang diteliti diperoleh saat pasien masuk rumah sakit. Uji statistic dilakukan dengan uji MannWhitney, T Test dan Chi-Kuadrat. Rerata kadar CK di pasien infark miokard akut yang tetap hidup dan meninggal selama perawatanadalah 507,38+749,62 U/L dan 1995,39+2290,06 U/L (p=0,002). Perbedaan tingkat angka kematian yang bermakna ditemukanantar kuartil CK (p=0,021). Kebahayaan relatif angka kematian pada kuartil keempat (4) sebesar 13 kali dibandingkan dengan kuartilkesatu (1) (selang kepercayaan 95%, 2,07-81,5; p=0,006), kuartil ketiga (3) sebesar 4,8 kali dibandingkan dengan kuartil kesatu (1)(selang kepercayaan 95%, 1,07-21,45; p=0,04) dan kuartil kedua (2) sebesar 3 kali dibandingkan dengan kuartil kesatu (1) (selangkepercayaan 95%, 0,68-13,3; p=0,148).Didasari telitian ini, ditemukan perbedaan bermakna kadar CK ditemukan saat masuk rumahsakit di pasien infark miokard akut yang tetap hidup maupun yang meninggal selama perawatan. Semakin tinggi kadar CK saat pasienmasuk rumah sakit semakin tinggi tingkat angka kematiannya.
INDEKS ATEROGENIK PLASMA DI PENYAKIT DIABETES MELITUS TIPE 2 (Atherogenic Index of Plasma in Type 2 Diabetes Mellitus) Amarensi M Betaubun; Uleng Bahrun; Ruland Pakasi
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 22, No 1 (2015)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v22i1.1228

Abstract

Atherogenic Index of Plasma (AIP) as a new marker of atherogenicity and directly related to the risk of atherosclerosis, is a simpleand inexpensive method to assess the severity of atherogenic dyslipidemia. 97% of adult patients with type 2 DM (T2DM) will havedyslipidemia including increased levels of TG, low HDL-C levels whereas LDL cholesterol levels had no effect. To determine the atherogenicindex of plasma in controlled and uncontrolled T2DM. A Cross-sectional study was conducted on 72 controlled T2DM samples and 112uncontrolled T2DM samples from Clinic of Endocrine and Methabolic dr Wahidin Sudirohusodo Hospital Makassar, starting from April-May 2013. Fasting glucose level, triglycerides, HDL-C and HbA1c determined using ABX Pentra 400 (colorimetric method). Data thenanalyzed with Mann Withney U test. Most of the samples are male, with the age range from 51-60 years old. Mean AIP is not so differentbetween the two groups (0.51±0.28 and 0.55±0.28 respectively). Fasting glucose level, triglycerides, HDL-C in T2DM uncontrolled werehigher than controlled. The atherogenic index of plasma of controlled T2DM group were 0.93 times lower than uncontrolled T2DM, MannWithney U test showed that there were no significant correlation between both of group (p>0.05). Atherogenic index of plasma cannotbe used to distinguish between controlled and uncontrolled T2DM.
MATRIKs METALOPROTEINASE-2 DI METASTASIS KARSINOMA PAYUDARA (Matrix Metalloproteinase-2 In Breast Cancer Metastastis) Besse Rosmiati; Uleng Bahrun; Ruland DN Pakasi
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 21, No 1 (2014)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v21i1.1251

Abstract

Matrix Metalloproteinase-2 is a family of extra cellular matrix degrading proteinases. Study results on the role of MMP-2 in breastcancer progression and metastasis are still controversial. The aim of this study was to know the MMP-2 level by analyzing in metastaticand non metastatic breast cancer patients by using a cross sectional design, it was carried out in the Wahidin Sudirohusodo, Ibnu Sina,Labuang Baji Hospitals and at the Research Unit of UNHAS Makassar from April 2012 until June 2012. The 56 breast cancer patientswere divided into two groups: metastatic and non metastatic based on their thorax photo, ultrasonography and/or bone scan results. Theywere also divided into early and advanced stage, based on their TNM staging. The matrix metalloproteinase-2 level was determined byELISA method. The result of this study showed that the mean levels of MMP-2 in metastatic and non metastatic breast cancer were 20.18ng/mL and 17.14 ng/mL, respectively. The independent sample T test showed there was a significant difference (p=0.018) in MMP-2levels between metastatic and non metastatic breast cancer. The mean level of MMP-2 in early and advanced stages was 17.10 ng/mLand 18.31 ng/mL, respectively, the independent sample T test showed no significant difference of MMP-2 level between both stages. Oneway ANOVA test showed no significant difference of MMP-2 level based on tumour size and regional lymph node infiltration. The MMP-2contributed to the metastasis in breast cancer patients. The matrix metalloproteinase-2 level in metastatic was higher than in the nonmetastatic breast cancer, so this condition could be used as a biomarker to predict the metastasis of breast cancer.
ANALISIS KADAR SERUM FERITIN DI KARSINOMA PAYUDARA (Analysis of Ferritin Levels in Carcinoma Mammae) Sriwati Atjo; Uleng Bahrun; Hardjoeno Hardjoeno
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 22, No 1 (2015)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v22i1.1219

Abstract

Carcinoma Mammae is a malignant disease originating from mammary parenchyma, and the second largest cause of death inthe world. Ferritin is a marker of neoplasia, which levels are increased in non-metastatic carcinoma mammae and more increased inmetastatic carcinoma mammae. This cross sectional study was conducted during June 2012 in carcinoma mammae patients of theWahidin Sudirohusodo Hospital, Ibnu Sina Hospital and Labuang Baji Hospital in Makassar. The aim of this study was to know theserum ferritin levels in metastatic and non-metastatic carcinoma mammae. In this study, 56 samples were obtained and grouped intometastatic and non-metastatic carcinoma mammae patients based on the Tumor, Node, Metastasis (TNM). Ferritin test was conductedby ECLIA method using Elecsys Analyzer Kit 2010 (Roche, USA). The study showed that the average ferritin concentration in advancedstage of carcinoma mammae (155.45 ng/mL) was higher than in the early stage (82.74 ng/m). The Mann Whitney test showed significantdifferences between the early and advanced stage (p=0.01), the median ferritin value in metastatic carcinoma mammae was higherthan non-metastatic (79.85 ng/mL). The Mann Whitney test showed significant differences between metastatic and non - metastaticcarcinoma mammae patients (p=0.00). Based on this study, it can be concluded, that ferritin levels can be used as a biomarker to predictthe progressivity of carcinoma mammae.
ANGKA BANDING NEUTROFIL/LIMFOSIT DI KARSINOMA PAYUDARA Yuly Eko Prasetyo; Uleng Bahrun; Ruland DN. Pakasi
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 21, No 2 (2015)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v21i2.1090

Abstract

Carcinoma Mammae (CM) is a malignancy of epithelial cells restricting at the breast ducts or lobes which causes very high mortalityrate. The Neutrophil/Lymphocyte ratio (NLR) is reflecting the inflamatory status, has been reported to be a prognostic indicator in somemalignant tumors. The purpose of this study is to know the NLR as an indicator of the progressivity of CM by analyzing it. A retrospectiveobservational study performed using data from the medical record of CM patients at Wahidin Sudirohusodo Hospital from January 2010up to December 2012. The diagnosis were established by the clinicians based on the result of histopathological exsamination, chest X-ray,abdominal ultrasound, bone scan and CT scan. The patients with surgical history, chemotherapy, radiotherapy, leukocytes >12.000/mm3and incomplete data were excluded from the analysis. The data distribution was analyzed using Kolmogorov-Smirnov test. The relationbetween NLR in CM was analized by One way ANOVA test and post hoc analysis. The result were 130 samples, consisting of 17 patientsin early stage, 71 in stage III and 42 in stage IV CM. In the early stage the mean of NLR were 1.69, 2.04 in stage III and 2.89 in stage IVand their differences were statistically significant (p<0.001). Post hoc analysis showed that the significant differences occurred betweenthe early stage and IV, as well as between stage III and IV. The mean of NLR were 2.28±1.02 in the non metastatic and 3.36±1.5 in themetastatic they were statistically significant (p<0.001). Based on the study results can be concluded that the neutrophil/lymphocyteratio can be used to assess the progressivity of CM. Further studies with larger samples were needed for the determination of the cut offpoint of NLR.